JP2010513552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513552A5 JP2010513552A5 JP2009543061A JP2009543061A JP2010513552A5 JP 2010513552 A5 JP2010513552 A5 JP 2010513552A5 JP 2009543061 A JP2009543061 A JP 2009543061A JP 2009543061 A JP2009543061 A JP 2009543061A JP 2010513552 A5 JP2010513552 A5 JP 2010513552A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- hydrogen
- halo
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87130206P | 2006-12-21 | 2006-12-21 | |
| US60/871,302 | 2006-12-21 | ||
| PCT/US2007/087044 WO2008076704A1 (en) | 2006-12-21 | 2007-12-11 | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513552A JP2010513552A (ja) | 2010-04-30 |
| JP2010513552A5 true JP2010513552A5 (cg-RX-API-DMAC10.html) | 2011-01-27 |
| JP5166441B2 JP5166441B2 (ja) | 2013-03-21 |
Family
ID=39186811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543061A Expired - Fee Related JP5166441B2 (ja) | 2006-12-21 | 2007-12-11 | 癌治療用イミダゾリジノニルアミノピリミジン化合物 |
Country Status (14)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2125794T1 (sl) | 2006-12-21 | 2011-02-28 | Lilly Co Eli | Spojine imidazolidinonil aminopirimidina za zdravljenje raka |
| EA016781B1 (ru) * | 2007-05-16 | 2012-07-30 | Эли Лилли Энд Компани | Триазолиламинопиримидиновые соединения |
| WO2008144222A2 (en) | 2007-05-16 | 2008-11-27 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| CN108853111B (zh) * | 2018-08-07 | 2020-06-05 | 浙江大学 | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| US6939877B2 (en) * | 2002-09-12 | 2005-09-06 | Wyeth | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans |
| WO2004063192A1 (en) * | 2003-01-10 | 2004-07-29 | Pharmacopeia Drug Discovery, Inc. | Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| JP2007533602A (ja) * | 2003-07-31 | 2007-11-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾチオフェン化合物及びそれらの使用 |
| AU2005316312B2 (en) | 2004-12-17 | 2009-10-22 | Amgen, Inc. | Aminopyrimidine compounds and methods of use |
| TW200800201A (en) * | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
| US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| SI2125794T1 (sl) | 2006-12-21 | 2011-02-28 | Lilly Co Eli | Spojine imidazolidinonil aminopirimidina za zdravljenje raka |
| EA016781B1 (ru) | 2007-05-16 | 2012-07-30 | Эли Лилли Энд Компани | Триазолиламинопиримидиновые соединения |
| WO2008144222A2 (en) | 2007-05-16 | 2008-11-27 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
-
2007
- 2007-12-11 US US12/516,514 patent/US8101628B2/en not_active Expired - Fee Related
- 2007-12-11 EA EA200970615A patent/EA016177B1/ru not_active IP Right Cessation
- 2007-12-11 AU AU2007334039A patent/AU2007334039B2/en not_active Ceased
- 2007-12-11 WO PCT/US2007/087044 patent/WO2008076704A1/en not_active Ceased
- 2007-12-11 JP JP2009543061A patent/JP5166441B2/ja not_active Expired - Fee Related
- 2007-12-11 KR KR1020097012835A patent/KR101088291B1/ko not_active Expired - Fee Related
- 2007-12-11 AT AT07855058T patent/ATE479680T1/de not_active IP Right Cessation
- 2007-12-11 BR BRPI0721045-0A patent/BRPI0721045A2/pt not_active IP Right Cessation
- 2007-12-11 DE DE602007008952T patent/DE602007008952D1/de active Active
- 2007-12-11 CN CN2007800472640A patent/CN101563342B/zh not_active Expired - Fee Related
- 2007-12-11 CA CA002671738A patent/CA2671738A1/en not_active Abandoned
- 2007-12-11 MX MX2009006634A patent/MX2009006634A/es active IP Right Grant
- 2007-12-11 ES ES07855058T patent/ES2349169T3/es active Active
- 2007-12-11 EP EP07855058A patent/EP2125793B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| JP2010523670A5 (cg-RX-API-DMAC10.html) | ||
| JP2017095457A5 (cg-RX-API-DMAC10.html) | ||
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| EP4242236A3 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
| JP2008044952A5 (cg-RX-API-DMAC10.html) | ||
| JP2011527666A5 (cg-RX-API-DMAC10.html) | ||
| JP2010501572A5 (cg-RX-API-DMAC10.html) | ||
| JP2012509265A5 (cg-RX-API-DMAC10.html) | ||
| WO2013166004A3 (en) | Organic compositions to treat kras-related diseases | |
| JP2012082227A5 (cg-RX-API-DMAC10.html) | ||
| JP2011500713A5 (cg-RX-API-DMAC10.html) | ||
| HUE037295T2 (hu) | RNS készítmény nem-kissejtes tüdõrák (NSCLC) kezelésére | |
| EP2311879A3 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
| WO2010094720A3 (en) | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| PT3199180T (pt) | Anticorpos epha3 para o tratamento de tumores sólidos | |
| GB0510584D0 (en) | Organic compounds | |
| JP2007510667A5 (cg-RX-API-DMAC10.html) | ||
| JP2017526662A5 (cg-RX-API-DMAC10.html) | ||
| CY1112570T1 (el) | Θεραπεια καρκινων με μετασταση | |
| JP2012509279A5 (cg-RX-API-DMAC10.html) | ||
| JP2012526766A5 (cg-RX-API-DMAC10.html) | ||
| ZA200706919B (en) | Pharmacogenomic markers for prognosis of solid tumors | |
| MY141780A (en) | 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics |